Aggressive B cell lymphoma
Conditions
Interventions
experimental group:GemOx+Rituximab
Sponsors
JiangSu Province Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed aggressive B cell lymphoma; 2. New-diagosis and untreated; 3. Age older than 70 years or older than 60 years with ECOG PS>=2; 4. Understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements.
Exclusion criteria
Exclusion criteria: 1. Inadequate hepatic, nephritic and cardiac function:total bilirubin, ALT, AST,Cr more than two fold of upper normal level. cardiac function more than Grade II; 2. Presence of Grade III nervous toxicity with two weeks; 3. HBV virus load (HBV DNA) >1*10E5 copies/ml; 4. Concomitant malignancy other than aggressive B cell lymphoma and need to treat; 5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary myelofibrosis) which investigator it unsuitable to be enrolled into this clinical trial; 6. Active and severe infectious diseases; 7. Major surgery within three weeks; 8. Any potential drug abuse, medical, psychological or social conditions which may disturb this investigation and assessment; 9. In any conditions which investigtor considered ineligible for this study; 10. Known sensitivity or allergy to investigational Product.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate;safety and toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;OS;mortality rate; | — |
Countries
China
Contacts
Public ContactWEI XU
Outcome results
None listed